Skinvisible Advances with Quoin Pharmaceuticals’ FDA Clearance

Skinvisible ( (SKVI) ) has issued an update.

Skinvisible announced significant achievements in 2024 and 2025 through its licensee, Quoin Pharmaceuticals, which has made progress in treating Netherton Syndrome using Skinvisible’s Invisicare technology. Quoin Pharmaceuticals received FDA clearance for a ‘whole body’ study and reported clinical improvements in studies, marking potential first FDA approval for a formulation using Invisicare, which may lead to a milestone payment to Skinvisible and ongoing royalties.

More about Skinvisible

Skinvisible Pharmaceuticals, a subsidiary of Skinvisible, Inc., is a research and development company specializing in topical and transdermal formulations with its patented Invisicare drug delivery technology. This technology is used to enhance the delivery of active ingredients in various treatments, including those for rare skin disorders like Netherton Syndrome.

YTD Price Performance: 22.94%

Average Trading Volume: 1,865

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $2.05M

Find detailed analytics on SKVI stock on TipRanks’ Stock Analysis page.